• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Regeneron touts launch of high-dose Eylea in battle with Roche's Vabysmo

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Nov 02, 2023 at 12:22: PM
via Roche’s surge in sales for its long-acting macular degeneration drug Vabysmo showed that patients in the market are open to switching to another treatment.

While that was bad news for Regeneron and its formerly dominant Eylea, the company has countered Roche with its own longer-acting formulation of the anti-VEGF drug.

article source
 




Top Bottom
Back
Quote